Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: LncRNA MCF2L-AS1 aggravates the malignant development of colorectal cancer via targeting miR-105-5p/RAB22A axis

Fig. 5

RAB22A neutralizes the suppressive effects of MCF2L-AS1 on CRC progression. A. The overexpression efficiency of RAB22A was examined by RT-qPCR assay. B and C. Cell proliferation in different rescue groups was evaluated by IF and EdU assays. D and E. The migration and invasion of cells in different groups were examined via Transwell assay. F and G. Cell apoptosis in different groups was assessed by flow cytometry assay and caspase-3/8/9 activity analysis. The statistical analysis of Fig. 5A-G was tested with one-way ANOVA. **P < 0.01

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us